Study #2024-1422
A first-in-human, phase 1a/1b trial to assess the safety, tolerability and preliminary efficacy of LY4170156, an antibody-drug conjugate targeting folate receptor alpha-expressing tumor cells, in participants with selected advanced solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
LY4170156, Itraconazole, bevacizumab, carboplatin, pembrolizumab
Description
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
Study phase:
Phase I
Physician name:
Shannon Westin
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.